Using AI-based technologies to classify AR-associated breast cancer subtypes based on the AR expression level (or expression pattern) plus the expression of ER, PR, or HER2 will help with the selection of treatments that may effectively benefit cancer patients. This evidence concerns the gene ESR1 and breast cancer.